Our history

Polpharma Biologics as an entity is a relatively new and innovative company, however it has nearly a century of history through having formerly been part of Polpharma.

We now operate in three international sites including one of the most advanced biologics manufacturing sites in Europe located near Warsaw in Poland.

1935

Polpharma established.

2000

Acquisition of Polpharma by Jerzy Starak, a committed and visionary entrepreneur who still controls Polpharma and Polpharma Biologics today.

2010

Polpharma, a leading pharmaceutical company in Poland and the central European region, launches biotech operations.

2013

Biotechnology R&D centre established in Gdańsk.

2014

Bioeq established - joint venture with Atos on the co-development of Ranibizumab.

2016

Acquisition of Bioceros BV, an early stage biotech development company in Utrecht, the Netherlands.

2018

Rapid development of the biotechnology R&D centre in Gdańsk.

2019

Creation of an independent Polpharma Biologics (spin-off from Polpharma). Out-licensing deal for Natalizumab with Sandoz. Out-licensing deal for Ranibizumab with Coherus.

2020

Duchnice manufacturing and development site joins Polpharma Biologics.

2021

2021 Bioeq, a joint venture of Polpharma Biologics Group, enters into an agreement with Teva to commercialize a biosimilar drug to Ranibizumab in Europe and Canada

Let’s collaborate and deliver quality biosimilars together.

Get in touch for more information.

Our history

Polpharma Biologics Growth Timeline

Let’s collaborate and deliver quality biosimilars together.